Wedbush Reaffirms “Outperform” Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VORGet Free Report)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $11.00 price target on the stock. Wedbush’s target price suggests a potential upside of 469.95% from the stock’s previous close. Wedbush also issued estimates for Vor Biopharma’s Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS and FY2028 earnings at $0.01 EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a report on Thursday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $14.44.

Check Out Our Latest Stock Report on VOR

Vor Biopharma Stock Performance

Shares of VOR opened at $1.93 on Thursday. The stock has a 50 day moving average price of $2.18 and a two-hundred day moving average price of $2.16. The firm has a market capitalization of $130.87 million, a P/E ratio of -1.10 and a beta of -0.38. Vor Biopharma has a 52 week low of $1.62 and a 52 week high of $6.18.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors have recently modified their holdings of the business. Bank of America Corp DE grew its holdings in shares of Vor Biopharma by 132.0% in the fourth quarter. Bank of America Corp DE now owns 3,942 shares of the company’s stock valued at $26,000 after acquiring an additional 2,243 shares in the last quarter. UBS Group AG purchased a new position in Vor Biopharma in the fourth quarter valued at approximately $27,000. Boothbay Fund Management LLC lifted its stake in Vor Biopharma by 36.4% in the first quarter. Boothbay Fund Management LLC now owns 19,536 shares of the company’s stock valued at $105,000 after purchasing an additional 5,216 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Vor Biopharma by 63.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 17,792 shares of the company’s stock valued at $96,000 after purchasing an additional 6,917 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Vor Biopharma by 28.2% in the second quarter. Renaissance Technologies LLC now owns 36,400 shares of the company’s stock valued at $112,000 after purchasing an additional 8,000 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

Vor Biopharma Company Profile

(Get Free Report)

Vor Biopharma Inc, a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies.

Recommended Stories

Analyst Recommendations for Vor Biopharma (NYSE:VOR)

Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.